Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.
نویسندگان
چکیده
http://bmj.com/cgi/content/full/329/7472/972 Updated information and services can be found at: These include: Data supplement http://bmj.com/cgi/content/full/329/7472/972/DC1 prices" "References w1 w16, further details and figures showing the effect on drug References http://bmj.com/cgi/content/full/329/7472/972#otherarticles 1 online articles that cite this article can be accessed at: http://bmj.com/cgi/content/full/329/7472/972#BIBL This article cites 17 articles, 5 of which can be accessed free at:
منابع مشابه
Issues for countries considering introducing the "fourth hurdle": the case of Hungary.
OBJECTIVES This study outlines the needs and current development of the "fourth hurdle" (i.e., requirement of effectiveness and cost-effectiveness data for drug coverage policy decisions) in Hungary, describes the legal background and seeks to address some of the most important questions in this field. METHODS The study draws on international experiences and discusses five issues that a given...
متن کاملClearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine
BACKGROUND New products evolving from research and development can only be translated to medical practice on a large scale if they are reimbursed by third-party payers. Yet the decision processes regarding reimbursement are highly complex and internationally heterogeneous. This study develops a process-oriented framework for monitoring these so-called fourth hurdle procedures in the context of ...
متن کاملAttitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs
Background Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some e...
متن کاملCost effectiveness of type 2 diabetes screening: A systematic review
Background: Although studies reported diabetes mellitus screening cost effective, the mass screening for type2 diabetes remains controversial. In this study we reviewed the recently evidence about the cost effectiveness of mass screening systematically. Methods: We reviewed the MEDLINE, Scopus, Web of Science (WOS), and Cochrane library databases by MeSH terms to identify relevan...
متن کاملUse of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden
Background The inclusion of cost-effectiveness data, as a basis for priority setting rankings, is a distinguishing feature in the formulation of the Swedish national guidelines. Guidelines are generated with the direct intent to influence health policy and support decisions about the efficient allocation of scarce healthcare resources. Certain medical conditions may be given higher priority ran...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- BMJ
دوره 329 7472 شماره
صفحات -
تاریخ انتشار 2004